These results might be attributed to a lack of IC biomarkers in the latter stages, even before induction of treatment, resulting in a lower response to IC treatment such as IDO1 inhibitors and PD-1/PD-L1 blockers in recurrent advanced NPC [38,39,40]. This evidence concerns the gene IDO1 and nasopharyngeal carcinoma.